Table 2 Clinical characteristics of study participants
Variable | Number of participants (n = 720) | Percentage (%) |
|---|---|---|
HIV type | ||
 Type 1 | 691 | 96.0 |
 Type 2 | 5 | 0.7 |
 Type 1 and 2 | 24 | 3.3 |
WHO stage of HIV | ||
 Stage I | 243 | 38.8 |
 Stage II | 193 | 26.8 |
 Stage III | 258 | 35.8 |
 Stage IV | 26 | 3.6 |
Past ARV experience | ||
 No | 705 | 97.9 |
 Yes | 15 | 2.1 |
Adherence to ART | ||
 Good | 373 | 51.8 |
 Fair | 254 | 35.3 |
 Poor | 93 | 12.9 |
Presence of other conditions | ||
 No | 640 | 88.9 |
 Yes | 80 | 11.1 |
Presence of opportunistic infection (s) | ||
 No | 642 | 89.2 |
 Yes | 78 | 10.8 |
Ever stopped or changed ARV | ||
 No | 685 | 92.4 |
 Yes | 55 | 7.6 |
ARV regimen | ||
 Efavirenz-based | 574 | 79.7 |
 Nevirapine-based | 63 | 8.8 |
 Lopinavir (PI)-based | 36 | 5.0 |
 Integrase-based | 47 | 6.5 |
ARV combinations | ||
 TDF/3TC/EFV | 501 | 69.6 |
 TDF/FTC/EFV | 5 | 0.7 |
 AZT/3TC/EFV | 44 | 6.1 |
 ABC/3TC/EFV | 7 | 1.0 |
 TDF/3TC/NVP | 34 | 4.7 |
 TDF/FTC/NVP | 2 | 0.3 |
 AZT/3TC/NVP | 44 | 6.1 |
 TDF/3TC/LPV/r | 29 | 4.0 |
 TDF/FTC/LPV/r | 4 | 0.6 |
 AZT/3TC/LPV/r | 3 | 0.4 |
 TDF/3TC/DTG | 47 | 6.5 |